G

Assistant Commissioner for Pater

Total Pages

Approved for use through 09/30/00. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Box Patent Application Washington, DC 20231

Residual Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL О (Only for new nonprovisional applications under 37 CFR 1.53(b))

[Total Pages 38]

First Named Inventor or Application Identifier

4821-406

John McCullough et al.

Attorney Docket No.

Express Mail Label No. N/A

ADDRESS TO:

9 9

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.

Fee Transmittal Form

Submit an original, and a duplicate for fee processing)

 Specification (preferred arrangement set forth below)

-Descriptive title of the Invention

- -Cross Reference to Related Applications
- -Statement Regarding Fed sponsored R&D
- -Reference to Microfiche Appendix
- -Background of the Invention
- -Brief Summary of the Invention
- -Brief Description of the Drawings (if filed)
- -Detailed Description of the Invention (including drawings, if filed)
- -Claim(s)
- -Abstract of the Disclosure
- □ Drawing(s) (35 USC 113)

[Total Sheets 0]

Oath or Declaration

[Total Sheets 2]

- a.

 Newly executed (original or copy)
- Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]

□ DELETION OF INVENTORS(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).

Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

- 6. D Microfiche Computer Program (Appendix)
- 7. D Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. D Computer Readable Copy
 - b.

 Paper Copy (identical to computer copy)
 - c.

 Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8.

 Assignment Papers (cover sheet & document(s))
- 9.

 37 CFR 3.73(b) Statement

 Power of Attorney (when there is an assignee)
- 10. □ English Translation Document (if applicable)
- Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
- 12. D Preliminary Amendment
- Return Receipt Postcard (MPEP 503)

(Should be specifically itemized)

- Small Entity

 Statement filed in prior application, Statement(s) Status still proper and desired
- Certified Copy of Priority Document(s) (if foreign priority is claimed)
- 16.
 Other:

7 .	If a CONTINUING APPLICATION	, check appropriate	box and supply	the requisite	informatio	on

Solution Section 20 Section Divisional

□ Continuation-in-part (CIP) of application no.

18. CORRESPONDENCE ADDRESS

☑ Customer Number or Bar Code Label

20582 (Insert Customer No. or Attach bar code label here)

or Correspondence address below

ADDRESS

NAME

CITY STATE ZIP CODE COUNTRY TELEPHONE FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior application:	Examiner	R. Cook	
• •	-		

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

This is a request for filing a \boxtimes continuation \square divisional application under 37 CFR § 1.53(b), of pending prior application no. 09/238,983 filed on January 28, 1999.

of John MCCULLOUGH and Paul D. RUBIN
(inventor(s) currently of record in prior application)

Art Unit__1614

for METHODS AND COMPOSITIONS FOR TREATING NICOTINE ADDICTION AND AIDING IN SMOKING
CESSATION USING OPTICALLY PURE (-)-BUPROPION
(title of invention)

1.

☐ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	119	-20	99	\$18.00 each	\$ 1,782.00
Independent	12	-3	9	\$80.00 each	\$ 720.00
	Basic Fee		\$ 710.00		
	Multiple Dependency Fee If Applicable (\$270.00)			270.00	
	Total		\$ 3,482.00		
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern			- \$ 0.00		
			Total Filing F	ee .	\$ 3,482.00

- 2. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
- 3. Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. 09/238,983 filed January 28, 1999.
- 4a.
 Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

	PENNIE & EDMONDS LLP KET
lb.	New formal drawings are enclosed.

Additional enclosures or instructions.

4b.		New formal drawings are enclosed.
4c.		Informal drawings are enclosed.
5a.		Priority of application no. filed on in is claimed under 35 U.S.C. §119.
5b.		The certified copy has been filed in prior application no., filed.
6.	⊠	The prior application is assigned of record to Sepracor Inc, as recorded at Reel 9850, Frame 0773.
7a.	⊠	The Power of Attorney appears in the original papers in the prior application no. 09/238,983, filed January 28, 1999.
7b.	0	Since the Power of Attorney does not appear in the original papers, a copy of the Power in prior application no., filed is enclosed.
8.		This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. is enclosed.
9.		The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. is the same as the content of the computer readable form submitted in application no

Respectfully submitted,

Date November 28, 2000

10.

45,479

Max Bachrach

(Reg. No.)

(Reg. No. 25,736)

For: Stanton T. Lawrence

PENNIE & EDMONDS LLP

1667 K Street, N.W.

Washington, D.C. 20006

(202) 496-4400

- 2 -